Glenmark Pharma slides 6% on deal to sell drug business to Nirma
Glenmark Pharma entered into a definitive agreement with Nirma Limited to divest a 75% stake in Glenmark Life Sciences at a price of ₹615/- per share for an aggregate consideration of ₹5,615 crore.